ICMR: Stop using rapid test kits of 2 chinese firms

The ICMR released a statement that, “Several States have procured rapid antibody test kits and on their demand, ICMR has also provided these kits with clear instructions that they are to be used only for surveillance purpose. Later some States raised issues regarding their performance during the testing exercise that they have undertaken.”

The ICMR, evaluated the kits of Guangzhou Wondfo Biotech and Zhuhai Livzon Diagnostics in field conditions and the results were different and showed variation in their sensitivity despite early promise of good performance for surveillance purposes. The release said, “States have now been told to not use these kits and return them to be sent back to the suppliers.’’

The single page note issued by the ICMR said the RT-PCR throat/nasal swab test was the best use for diagnosis of COVID -19. It detected the virus early and was the best strategy to identify and isolate the individual.

  • Related Posts

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    Patients for Patient Safety Foundation (PFPSF) Partners with CAHO to RollOut an Excellence Program New Delhi: Thanks to some well-meaning organizations, patients are going to be lord of all they…

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    BMJ Research Forum all set to mull over in Delhi on September 5 New Delhi: Research in healthcare in India is a dime a dozen. But the real question that…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Three arrested after liquor bottles found at pharma firm

    Three arrested after liquor bottles found at pharma firm

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Gujarat FDCA cracks down on four firms for illegal drug sale; cancels licences of two

    Gujarat FDCA cracks down on four firms for illegal drug sale; cancels licences of two